陈扬,刘洪序,陈浩,万尊慧,董帅,宋兵

• 1:兰州大学第一医院心血管外科
• 2:兰州大学第一临床医学院

摘要(Abstract)：

目的 应用Meta分析评估射频消融治疗梗阻性肥厚型心肌病的有效性及安全性。方法 计算机检索PubMed、EMbase、The Cochrane Library、Web of Science、中国期刊全文数据库（CNKI）、万方数据知识服务平台、维普中文科技期刊全文数据库，检索时限均为从建库至2022年5月16日，按照纳入与排除标准独立筛选文献、提取资料，并评价纳入研究的质量，采用Stata 16.0软件进行Meta分析。结果 最终纳入13篇研究，共计387例患者。Meta分析结果显示，射频消融治疗后，患者术后静息状态左心室流出道压力阶差（LVOTG;WMD=55.85,95%CI49.36～62.34,P<0.001）和术后激发状态LVOTG(WMD=95.58,95%CI75.77～115.38,P<0.001)均有明显改善，差异均有统计学意义。术后室间隔厚度（WMD=4.06,95%CI1.66～6.46,P<0.001）和纽约心脏病协会心功能分级（WMD=1.26,95%CI0.94～1.58,P<0.001）较术前均有所改善，差异均有统计学意义。结论 应用射频消融术来治疗梗阻性肥厚型心肌病可以缓解患者的临床症状并改善预后。射频消融治疗有望成为一种新型的、有前途的替代治疗方法。

关键词(KeyWords)： 射频消融术;梗阻性肥厚型心肌病;安全性;Meta分析

Abstract:

Keywords:

基金项目(Foundation): 甘肃省自然科学基金项目（20JR10RA689）;; 甘肃省青年科技基金计划项目（21JR1RA104）;; 兰州大学第一临床医学院卓越计划项目（20200060024）

作者(Author): 陈扬,刘洪序,陈浩,万尊慧,董帅,宋兵

参考文献(References)：

• [1] Maron BJ,Shirani J,Poliac LC,et al. Sudden death in young competitive athletes. Clinical,demographic,and pathological profi les[J]. JAMA,1996,276(3):199-204.
• [2]朱昌盛，陈海波，王水云，等.改良扩大Morrow手术治疗青少年肥厚型梗阻性心肌病患者的早期疗效分析[J].中国循环杂志，2016,31(6):583-587.
• [3] Maron MS,Olivotto I,Betocchi S,et al. Effect of l e ft ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,348(4):295-303.
• [4]王艳微，徐璐，苗成龙.肥厚型梗阻性心肌病经皮心内膜射频消融治疗进展[J].中国介入心脏病学杂志，2022,30(1):55-57.
• [5] Elliott PM,Anastasakis A,Borger MA,et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy:the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
• [6] Raphael CE,Cooper R,Parker KH,et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy:insights from wave intensity analysis and magnetic resonance[J]. J Am Coll Cardiol,2016,68(15):1651-1660.
• [7] Yoshinaga M,Yoshikawa D,Ishii H,et al. Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy[J]. Int Heart J,2015,56(4):415-420.
• [8] Spoladore R,Maron MS,D'amato R,et al. Pharmacological treatment options for hypertrophic cardiomyopathy:high time for evidence[J]. Eur Heart J,2012,33(14):1724-1733.
• [9] Spertus JA,Fine JT,Elliott P,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):health status analysis of a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2021,397(10293):2467-2475.
• [10] Pelliccia F,Seggewiss H,Cecchi F,et al. Septal ablation versus surgical myomectomy for hypertrophic obstructive cardiomyopathy[J]. Curr Cardiol Rep,2021,23(11):165.
• [11] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet,1995,346(8969):211-214.
• [12] Chan W,Williams L,Kotowycz MA,et al. Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy[J].Can J Cardiol,2014,30(8):912-919.
• [13] Tuohy CV,Kaul S,Song HK,et al. Hypertrophic cardiomyopathy:the future of treatment[J]. Eur J Heart Fail,2020,22(2):228-240.
• [14] Lawrenz T,Kuhn H. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy[J]. Z Kardiol,2004,93(6):493-499.
• [15]刘丽文，李静，鲁孝楠，等.梗阻性肥厚型心肌病的治疗新进展[J].中华医学超声杂志（电子版），2021,18(1):4-7.
• [16] Zhou M,Ta S,Hahn RT,et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy[J]. JAMA Cardiol,2022,7(5):529-538.
• [17]蒋周芩，舒茂琴，柴虹，等. CARTOSound引导下射频消融治疗肥厚型梗阻性心肌病患者的临床效果[J].第三军医大学学报，2021,43(8):736-740.
• [18]葛迎辉，魏小云，赵信科.三维超声指导下室间隔射频消融治疗肥厚梗阻性心肌病术后疗效观察[J].中国循证心血管医学杂志，2021,13(4):405-408.
• [19]蔡迟，王靖，楚建民，等.心内膜室间隔射频消融治疗肥厚型梗阻性心肌病的疗效分析[J].中国心脏起搏与心电生理杂志，2021,35(4):325-330.
• [20]白瑾，刘书旺，冯新恒，等. CartoSound指导下肥厚型梗阻性心肌病射频消融治疗[J].中国心脏起搏与心电生理杂志，2021,35(1):7-11.
• [21] Qian D,Zhou X,Liu H,et al. Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy[J]. J Clin Ultrasound,2021,49(6):554-562.
• [22]贾玉和，林瑶，刘俊，等.在心内三维超声指导下经皮心内膜室间隔射频消融术治疗肥厚型梗阻性心肌病合并晕厥的临床应用研究[J].中国循环杂志，2020,35(7):638-644.
• [23]陶海龙，龙德勇，赵江涛，等.心腔内超声三维标测指导下经皮射频消融室间隔治疗肥厚型梗阻性心肌病[J].郑州大学学报（医学版），2019,54(6):899-902.
• [24] Shelke AB,Menon R,Kapadiya A,et al. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy[J]. Indian Heart J,2016,68(5):618-623.
• [25] Crossen K,Jones M,Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy[J].Heart Rhythm,2016,13(9):1885-1890.
• [26] Cooper RM,Shahzad A,Hasleton J,et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy:a novel use of CARTOSound?technology to guide ablation[J].Europace,2016,18(1):113-120.
• [27] Sreeram N,Emmel M,de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children[J]. J Am Coll Cardiol,2011,58(24):2501-2510.
• [28] Lawrenz T,Borchert B,Leuner C,et al. Endocardial r a d i o f r e q u e n c y a b l a t i o n f o r h y p e r t r o p h i c o b s t r u c t i v e cardiomyopathy acute results and 6 months'follow-up in 19patients[J]. J Am Coll Cardiol,2011,57(5):572-576.
• [29]罗明尧，王水云，孙宏涛，等.肥厚型梗阻性心肌病外科治疗术后并发完全性房室传导阻滞的探讨[J].中华心血管病杂志，2013,41(7):598-601.
• [30]然鋆，宋云虎，胡盛寿，等.改良Morrow术治疗经皮室间隔消融术后的肥厚型梗阻性心肌病[J].中国分子心脏病学杂志，2017,17(2):2009-2011.
• [31] Veselka J,Lawrenz T,Stellbrink C,et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy:a European multicenter and multinational study[J]. Catheter Cardiovasc Interv,2014,84(1):101-107.
• [32] Liebregts M,Vriesendorp PA,Mahmoodi BK,et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy[J]. JACC Heart Fail,2015,3(11):896-905.
• [33] Guo HC,Li JH,Jiang TY,et al. Comparison of clinical ef fects between percutaneous transluminal septal myocardial ablation and modifi ed morrow septal myectomy on patients with hypertrophic cardiomyopathy[J]. Chin Med J(Engl),2018,131(5):527-531.
• [34] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/A C C guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. Circulation,2020,142(25):e533-e557.
• [35]刘丽文，左蕾，周梦垚，等.经胸超声心动图引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病的安全性和有效性[J].中华心血管病杂志，2019,47(4):284-290.
• [36] Maron BJ,Maron MS,Wigle ED,et al. The 50-year history,controversy,and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2009,54(3):191-200.